MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a significant step forward in MEDIPOST's mission to...
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. The trial previously demonstrated that...
HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers “One Drug, Multiple Screens” in Autoimmune New Drug R&D
BOSTON and SUZHOU, China, June 3, 2026 /PRNewswire/ -- HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates standardized rodent models with continuously developing non-human primate (NHP) research capabilities. It aims to support global innovative drug R&D institutions in conducting efficacy evaluation,...
KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market
Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation Award ZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that its KrystoLens, the single-use neuro-endoscope, has officially received certification from the Taiwan Food and Drug Administration (TFDA), marking an important milestone in the company's development in medical imaging and endoscopic applications. ...
NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
ZURICH, June 3, 2026 /PRNewswire/ -- Swiss luxury beauty brand NIANCE is entering a new phase of growth with the launch of an integrated beauty and longevity ecosystem combining skincare, supplementation, diagnostics, treatments, recovery, and wellness experiences. HOUSE OF NIANCE ZURICH Known for its science-backed approach to healthy...
CAS Connections brings trusted scientific data and AI to leading R&D platforms
CAS announces strategic collaborations to embed reliable scientific data and CAS Newton agentic AI into leading workflow tools to increase research efficiency COLUMBUS, Ohio, June 3, 2026 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, today announced CAS Connections, a new integration framework that...
SKINCEUTICALS BECOMES OFFICIAL SKINCARE PARTNER OF SCUDERIA FERRARI HP
NEW YORK, June 3, 2026 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide, is embarking on a new track, becoming an Official Partner of Scuderia Ferrari HP, the iconic Formula 1 racing team. Marking Scuderia Ferrari HP's first-ever skincare partnership, the multi-year partnership will bring together two brands united...
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will present the first preclinical...
New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles. Results revealing no complications and high satisfaction prove the need to adapt surgical techniques for variations in skin type between Asian and Caucasian patients. SINGAPORE, June 3, 2026 /PRNewswire/ -- The evaluation and management...
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7-H3 ADC SKB500 in patients with advanced solid tumors were...
